Serum neurofilament light chain in patients with acute cerebrovascular events

Marchis, Gian Marco De; Katan, Mira; Barro, Christian; Fladt, Joachim; Traenka, Christopher; Seiffge, David J; Hert, Lisa; Gensicke, Henrik; Disanto, Giulio; Sutter, Raoul; Peters, Nils; Sarıkaya, Hakan; Goeggel-Simonetti, Barbara; El-Koussy, Marwan; Engelter, Stefan T.; Lyrer, Philippe; Christ‐Crain, Mirjam; Arnold, Marcel; Kuhle, Jens; Bonati, Leo H.

doi:10.1111/ene.13554

Cited by 80 publications

(71 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are consistent with past studies showing that serum levels of NF-L are higher in people with diverse neurological and neurodegenerative conditions. Researchers have reported that serum levels of NF-L are higher in people with multiple sclerosis (Kuhle et al, 2016;Disanto et al, 2017;Kuhle et al, 2017;Novakova et al, 2017), acute ischemic stroke (De Marchis et al, 2018), active cerebral small vessel disease (Gattringer et al, 2017), familial Alzheimer's disease (Mattsson et al, 2017;Weston et al, 2017), Huntington's disease (Byrne et al, 2017), frontotemporal dementia (Rohrer et al, 2016), Creutzfeldt-Jakob disease (Thompson et al, 2018), Parkinsonian disorders (Hansson et al, 2017), other degenerative ataxias such as multiple system atrophy (Wilke et al, 2018) and amyotrophic lateral sclerosis (Feneberg et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

“…Because older adults are more likely to have neurological conditions prior to brain injury, NF-L might be elevated differentially in older adults, compared to middle-aged or younger adults, following mild traumatic brain injury (MTBI). A number of studies indicate that serum NF-L levels are higher in people with diverse neurological and neurodegenerative diseases (Kuhle et al, 2016;Rohrer et al, 2016;Byrne et al, 2017;Disanto et al, 2017;Gattringer et al, 2017;Hansson et al, 2017;Kuhle et al, 2017;Mattsson et al, 2017;Novakova et al, 2017;Weston et al, 2017;De Marchis et al, 2018;Feneberg et al, 2018;Thompson et al, 2018;Wilke et al, 2018). Therefore, as a potential diagnostic or prognostic biomarker for neurotrauma, it is important to determine whether there is an association between age and NF-L levels in individuals who sustain MTBIs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries

Iverson

Reddi

Posti

et al. 2019

Journal of Neurotrauma

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries

Iverson

Reddi

Posti

et al. 2019

Journal of Neurotrauma

View full text Add to dashboard Cite

“…For example, plasma glial fibrillary acidic protein shows > 90% specificity as a biomarker for haemorrhagic stroke, and concentrations are positively correlated with the risk of subsequent clinical deterioration [64]. Neurofilaments are released during neuroaxonal injury [68], including following traumatic brain injury [69], but are also elevated in active cerebral small vessel disease [70] and acute ischaemic stroke [71], particularly in those with higher severity of primary injury [72] and recurrent ischaemic lesions [71]. These markers may prove a valuable avenue of investigation for further studies of END.…”

Section: Recommendationsmentioning

confidence: 99%

A Systematic Review and Meta-Analysis of Molecular Biomarkers Associated with Early Neurological Deterioration Following Acute Stroke

Martin

Price

2018

Cerebrovasc Dis

View full text Add to dashboard Cite

Background: Early neurological deterioration (END) following acute stroke is associated with poorer long-term outcomes. Identification of patients at risk could assist early monitoring and treatment decisions. This review summarised the evidence describing non-radiological biomarkers for END. Summary: Electronic searches from January 1990 to March 2017 identified studies reporting a blood/cerebrospinal fluid (CSF)/urine biomarker measurement within 24 h of acute stroke and at least 2 serial assessments of clinical neurological status (< 24 h and < 7 days). Out of 12,895 citations, 82 studies were included, mostly focusing on ischaemic stroke. Using higher neurological thresholds, the n-weighted END incidence for ischaemic stroke was 11.9% (95% CI 11.4–12.4%) and 18.6% (17.9–19.2%) for lower thresholds. Incidence decreased with advancing study publication year (Pearson r-squared 0.23 and 0.15 for higher and lower threshold studies). After classification into 3 broad categories, meta-analysis showed that biomarkers associated with increased END risk (n; fixed-effects mean difference; 95% CI) were “metabolic” (glucose [n = 9,481; 0.90 mmol/L; 0.74–1.06], glycosylated haemoglobin [n = 3,146; 0.33%; 0.19–0.46], low-density lipoprotein [n = 4,839; 0.13 mmol/L; 0.06–0.21], total cholesterol [n = 4,762; 0.21 mmol/L; 0.11–0.31], triglycerides [n = 4,820; 0.11 mmol/L; 0.06–0.17], urea [n = 1,351; 0.55 mmol/L; 0.14–0.96], decreasing albumin [n = 513; 0.33 g/dL; 0.05–0.61]); “inflammatory and excitotoxic” (plasma glutamate [n = 688; 60.13 µmol/L; 50.04–70.22], CSF glutamate [n = 369; 7.50 µmol/L; 6.76–8.23], homocysteine [n = 824; 2.15 µmol/L; 0.68–3.61], leucocytes [n = 3,766; 0.54 × 10⁹/L; 0.34–0.74], high-sensitivity C-reactive protein [n = 1,707; 3.79 mg/L; 1.23–6.35]); and “coagulation/haematological” (fibrinogen [n = 3,132; 0.32 g/L; 0.25–0.40]; decreasing haemoglobin [n = 3,586; 2.38 g/L; 0.15–4.60]). Key Messages: Declining incidence of END may represent improving care standards; however, it remains a frequent occurrence. Although statistical associations exist between biomarkers and an increased risk of END, the most promising still need prospective evaluation to determine their additional value relative to baseline radiological and clinical characteristics.

show abstract

“…Elevated levels of neurofilament light chain (NFL) in sera or in the cerebrospinal fluid (CSF) represent neuroaxonal damage and are proposed to have a predictive value concerning outcomes in patients suffering from inflammatory, neurodegenerative, and cerebrovascular diseases …”

Section: Introductionmentioning

confidence: 99%

CSF Neurofilament light chain level predicts axonal damage in cerebral vasculitis

Pawlitzki

Butryn

Kirchner³

et al. 2019

Ann Clin Transl Neurol

View full text Add to dashboard Cite

The rarity of primary angiitis of the central nervous system (PACNS) demands diagnostic and prognostic biomarkers. We retrospectively measured Neurofilament light chain (NFL) concentrations in cerebrospinal fluid in a severely relapsing PACNS patient at multiple time points during the course of the disease. A marked increase in NFL levels preceding the onset of neuro‐axonal damage and arterial‐vessel abnormalities was observed with magnetic resonance imaging as well as with MR‐ and conventional angiography. Thus, marked elevation of NFL in PACNS seems to occur ahead of definitive radiological abnormalities and might serve as a diagnostic biomarker.

show abstract

Serum neurofilament light chain in patients with acute cerebrovascular events

Abstract: In conclusion, among patients admitted within 24 h of AIS or TIA onset, admission sNfL levels were associated with clinical severity on admission and TIA diagnosis, but not with infarct size on MR-DWI acquired on admission or functional outcome at 3 months.

Cited by 80 publications

References 19 publications

Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries

Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries

A Systematic Review and Meta-Analysis of Molecular Biomarkers Associated with Early Neurological Deterioration Following Acute Stroke

CSF Neurofilament light chain level predicts axonal damage in cerebral vasculitis

Contact Info

Product

Resources

About